Outbound Pharma’s Post

Exclusive insights from Claudia Palme, Senior Executive Advisor, Strategy& Middle East, part of the PwC network: Unlocking the Potential of Saudi Arabia's Pharma Market. Unlock the potential of the Middle East and Africa’s most profitable pharma market with insights from Claudia Palme, Senior Executive Advisor at Strategy&, part of the PwC Network. Discover why Saudi Arabia is not just a regional leader but a critical player on the global pharma stage. Claudia sheds light on the significant government support that is fueling the growth of a robust pharma ecosystem in Saudi Arabia. From integrated value chains to strategic industry expansions, learn how CPHI Middle East is instrumental in bringing together major players to amplify their global footprint. 📅 From 10-12 December 2024, be a part of the largest pharma gathering in the region. Join CPHI Middle East to connect, collaborate, and capitalize on unparalleled business opportunities in Saudi Arabia and Africa’s thriving markets. Book your stand today. 🔗 Get involved: https://lnkd.in/dFazGGNZ 🗓 10 - 12 Dec 2024 📍 Riyadh, Saudi Arabia #AtTheHeartofPharma #cphime #cphi #pharmaceuticals #biotech #saudivision2030 #healthcare #pharma #pharmasupplychain #drugdiscovery #pharmaceuticalmanufacturing #medicine #lifescience #drugdelivery #sustainability #biopharma #innovationsinhealthcare #datadriven #pharmaexhibition #pharmaevent #pharmaconference #saudiarabia #riyadh #Tahaluf

🌟 Proud Moment for Localized Healthcare in Saudi Arabia! 🌟 I’m excited to share a significant step forward in advancing healthcare in the Kingdom. Sudair Pharmaceutical Company, in collaboration with Sanofi & National Unified Procurement Company "NUPCO" is making strides towards localizing #Insulin production in Saudi Arabia. This initiative isn’t just about meeting the growing demand for insulin in the region but about creating a robust, sustainable supply chain that caters to our unique healthcare landscape. By fostering local production, we aim to: • Ensure reliable access to life-saving insulin for patients across the Kingdom. • Reduce dependency on international supply chains. • Support national goals outlined in Saudi Vision 2030 to enhance self-sufficiency and localize essential industries. This collaboration is a testament to our shared commitment to empowering healthcare, uplifting our economy, and, most importantly, serving the people of Saudi Arabia. Stay tuned as we continue to make healthcare history together! 💪🌍 #Insulin #SaudiVision2030 #SudairPharma #Sanofi

🌟 Ready to Make a Difference at CPHI Middle East 2024! 🌟 As the global pharmaceutical industry converges on Riyadh from 10-12 December, we’re proud to be part of the conversation shaping the future of health and wellness in the MENA region. Unlocking Market Potential Together With Saudi Arabia emerging as a powerhouse for pharma innovation, fueled by healthcare advancements and a drive for excellence, CPHI Middle East offers unparalleled opportunities to connect, collaborate, and grow. We’re here to engage with leaders, innovators, and partners who are ready to redefine what’s possible in pharmaceuticals. Your Trusted Partner At Alkan Chemical Europe, our focus has always been on delivering high-quality APIs, excipients, and raw materials that meet your most demanding needs. From precise formulation support to seamless logistics through our supply chain, we are here to empower your success and deliver value at every step. 💬 Let’s Connect! If you’re seeking innovative solutions and strategic growth opportunities, we’d love to meet and explore how we can drive success together. 📧 info@alkan-chemical.com 🔗 alkan-chemical.com 📞 +49 211 240 88 117 #CPHIMiddleEast2024 #PharmaceuticalInnovation #AlkanChemicalEurope #Riyadh #PharmaGrowth #StrategicPartnerships #QualitySolutions #UnlockingPotential #CollaborateToInnovate #EmergingMarkets

#SaudiArabiaPharmaceuticals #PharmaceuticalsMarket #SaudiArabia #Healthcare #PharmaceuticalIndustry #MarketOverview #GrowthPotential #MiddleEasternTrends #PharmaceuticalTrends #HealthcareIndustry Saudi Arabia Pharmaceuticals Market Share, Size, Growth, and Forecast 2024-2032 The Saudi Arabia pharmaceuticals market size reached US$ 9.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 2.52% during 2024-2032. The market is being driven by factors such as the country's growing population, increasing prevalence of chronic diseases, government investments in healthcare infrastructure, rising healthcare spending, technological advancements, collaborations between local and international pharmaceutical companies, the growing trend of medical tourism, and changing demographics. Request a Sample Report: https://lnkd.in/g2QU5kC2 The pharmaceuticals market in Saudi Arabia is experiencing rapid growth, driven by increasing urbanization, rising healthcare spending, and government initiatives promoting healthcare development. Read Full Report: https://lnkd.in/gP2KaNai

Pharmaceutical Industry Growth: Just the Right Pill for Saudi Arabia’s Healthcare Goals. Saudi Arabia’s Vision 2030 is Transforming Healthcare! As the Kingdom invests heavily in healthcare infrastructure, the demand for pharmaceuticals is soaring. The local pharma market is expected to reach $5.53 billion by 2024 and grow to $6.93 billion by 2029. 🔹 Fueling Local Innovation: The Kingdom’s push for localization means more than just numbers. By producing key medications locally, Saudi Arabia is reducing costs, enhancing access, and making the healthcare sector more resilient. Notable collaborations like Boehringer Ingelheim’s partnership with Alpha Pharma are setting the stage for Saudi Arabia to become a regional biotech hub. 🔹 Empowering the Economy: The Saudi government is driving this transformation with incentives, tax breaks, and streamlined regulations. By 2030, these initiatives will generate 11,000 jobs and contribute $34.6 billion to the non-oil GDP, firmly positioning the Kingdom as a global leader in pharmaceutical manufacturing and research. 🔹 Beyond the Pill: Localization isn't just about producing meds—it’s about securing a sustainable, innovative future for Saudi Arabia's healthcare sector. With the right policies and partnerships, the Kingdom is set to achieve its ambitious healthcare goals and solidify its role as a leader in the life sciences. Let’s connect and discuss how this evolving landscape is creating opportunities for investors, businesses, and communities in Saudi Arabia! #SaudiVision2030 #PharmaceuticalIndustry #HealthcareInnovation #SaudiArabia #BusinessStrategy #RealEstateAdvisory #InvestmentOpportunities #shan

Reflecting on Milestones: Advancing Algeria's Healthcare Together In June, Sanofi Algeria and Saidal Group marked a new chapter in algerian healthcare with the signing of a pioneering partnership to produce second generation insulins right here in Algeria, in full process. This is a testament to our commitment to the nation’s pharma industry and, most importantly, to the patients who rely on safe, consistent access to essential treatments. Leading these negotiations and foundational steps alongside our partners has been an honor for me and a journey of teamwork, dedication, and resilience. With this collaboration, we’re not just strengthening ties between two companies; we’re reinforcing a shared vision for a healthier future in Algeria—one that puts high-quality products in the hands of those who need them without uncertainty about supply or availability. This milestone is not just about insulin; it’s about setting a precedent for locally driven innovation and access to world-class healthcare. I am incredibly proud of this achievement and what it means for our industry, our partners, and, above all, for the algerian patients. #HealthcareAccess #LocalProduction #PharmaInnovation #Sanofi #SaidalGroup #PartnershipForPatients

Grateful for the discussion panel that shed light on the nuances of entering the Saudi Arabia pharmaceutical market, which is projected to reach $21 billion by 2030, growing at a CAGR of 7.6% at CpHI Middle East in Riyadh, Dec 10, 2024. A key takeaway. The right partner is essential. Market entry is rarely successful without strong, localized partnerships that align with your goals and regulatory needs. Building such relationships isn’t just a step—it’s a foundation. Additionally, investing in networking can unlock significant future export opportunities, helping organizations navigate this rapidly growing and competitive market. A heartfelt thanks to Haider Hussein, Kassem Younes, and Abdel Fattah Irsheid for sharing their expertise and insights during the panel. #pharmamarketentry #exportpharma

As part of its Vision 2030, Saudi Arabia is making significant strides in transforming its healthcare sector, with a particular focus on the pharmaceutical industry. The Kingdom is set to see impressive growth, with the market projected to reach $6.93 billion by 2029. Key to this expansion is the localization of pharmaceutical manufacturing, enhancing the country's self-sufficiency and resilience. Not only does this reduce reliance on imports, but it also paves the way for Saudi Arabia to become a regional biotech hub. Initiatives targeting non-communicable diseases, such as Type-2 diabetes, have already seen success, with partnerships between global pharma giants and local companies taking center stage. This localization push is creating thousands of jobs, fostering innovation, and attracting global investments, all while aligning with the Kingdom’s broader goals of economic diversification and enhanced healthcare access. With ongoing government support, including tax incentives and regulatory reforms, Saudi Arabia is well on its way to becoming a leader in pharmaceutical research, manufacturing, and innovation. #Vision2030 #Healthcare #Innovation #SaudiArabia #KSA https://okt.to/Fh9Tdj

A Major Advancement in #Pharmaceutical and #MedicalDevice #Regulation! Dr. Ahmed Mohammed Al Ansari, Chief Executive of the #NationalHealthRegulatoryAuthority (NHRA), and Dr. Hisham Saad Al Jadhey, CEO of the #SaudiFoodandDrugAuthority (SFDA), have signed a pivotal #MemorandumofUnderstanding (MoU), aimed at enhancing #Cooperation between Bahrain and Saudi Arabia. The signing was honored by the presence of Lieutenant General Dr. Shaikh Mohamed bin Abdullah Al Khalifa, Chairman of the #SupremeCouncilofHealth (SCH). Dr. Al Ansari highlighted that this MoU allows Bahrain to recognize and approve pharmaceuticals and medical devices already authorized by Saudi Arabia’s SFDA, significantly streamlining #RegulatoryProcesses and strengthening the healthcare sectors of both nations. This collaboration builds upon the 2019 agreement between NHRA and SFDA, further aligning #Healthcare standards and improving #Access to essential healthcare products. #Healthcare #Pharmaceuticals #MedicalDevices #Bahrain #SaudiArabia #GCC #MENA #Collaboration #RegulatoryAffairs #NHRA #SFDA #SCH #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Announcing the 3rd Meeting of OIC Heads of National Medicines Regulatory Authorities Saudi Arabia, represented by SFDA, hosts the 3rd Organization of Islamic Cooperation (OIC) Heads of National Medicines Regulatory Authorities (NMRAs) meeting on Dec 17-18. The event focuses on advancing medicine regulation and R&D ecosystems. Chaired by SFDA CEO Dr. Hisham S. Aljadhey, with 51 participants attending. Key topics: regulatory harmonization, biotechnology, and affordable medicines. The meeting aligns with SDGs, enhancing public health and safety. Saudi Arabia reaffirms its commitment to global health and innovation. Collaboration aims to ensure access to safe, high-quality medicines. A significant step towards regulatory excellence and public health. News Source: https://lnkd.in/gJQ-XxKP #SFDA #OIC #MedicinesRegulation #Healthcare #PublicHealth #GlobalHealth #Innovation #RDEcosystems #Biotechnology #AffordableMedicines #RegulatoryHarmonization #SDGs #Pharmaceuticals #DrugSafety #HealthcareInnovation #PharmaIndustry #MedicalRegulation #HealthSecurity #PatientSafety #HealthcareQuality